Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AstraZeneca PLC Remuneration Information 2013

Aug 1, 2013

5229_dirs_2013-08-01_c01cd78c-adb2-41de-8b9e-378807b1c857.html

Remuneration Information

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7244K

AstraZeneca PLC

01 August 2013

Transactions by Person Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

On 1 August 2013, Marc Dunoyer, EVP, Global Portfolio & Product Strategy, a person discharging managerial responsibilities, was granted awards under the terms of the AstraZeneca Investment Plan (AZIP), the AstraZeneca Performance Share Plan (AZPSP) and the AstraZeneca Restricted Share Plan (AZRSP) over the Company's Ordinary Shares of US$0.25 each.  A summary of these plans can be found in the AstraZeneca Annual Report and Form 20-F Information 2012 which is available on the Company's website www.astrazeneca.com.

Name Shares awarded under AZIP Shares awarded under AZPSP Shares awarded under AZRSP Award price per share
Marc Dunoyer 8,176 90,853 65,505 3302p

The AZIP award is subject to a four-year performance period (1 January 2013 to 31 December 2016) and a subsequent four-year holding period (1 January 2017 to 31 December 2020).

The AZPSP award is subject to a three-year performance period (1 January 2013 to 31 December 2015).

More information about the performance measures that relate to the AZIP and the AZPSP awards is set out in the Remuneration Committee Chairman's Speech and Presentation which was presented to shareholders at the Company's 2013 AGM, and which can be found at www.astrazeneca.com/Investors/Shareholder-information/Annual-General-Meeting.

The AZRSP award will vest as follows:

9,103 shares will vest on 15 June 2014 subject to Mr Dunoyer's continued employment with the Company

41,472 shares will vest on 15 June 2015 subject to Mr Dunoyer's continued employment with the Company

14,930 shares will vest on 1 August 2016 subject to the same performance conditions as the AZPSP award

Mr Dunoyer commenced employment with the Company on 15 June 2013.  All of the awards, which were approved by the Remuneration Committee, result from a combination of the normal operation of the Company's long-term incentive plans for 2013 and arrangements to compensate Mr Dunoyer for the forfeiture of unvested long-term incentive awards from his previous employer.

A C N Kemp

Company Secretary

1 August 2013

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSUAARRORAWRAR